Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
677 participants
OBSERVATIONAL
2010-07-01
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A single-center, cohort observational clinical outcomes study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System
NCT02036931
Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System
NCT04079114
AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study
NCT03357445
Cementless Oxford Partial Knee Controlled Observational Study
NCT02350049
Database Retrieval for the Comprehensive Shoulder
NCT03409718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives: Primary Objectives:
Clinical performance - as measured by clinical score data (HHS, WOMAC and Oxford Hip Score), radiographic as-sessments and survivorship which will be based on removal of the device.
Secondary Objectives:
Safety will be evaluated by monitoring incidence of adverse events. Length of study: 13 years (3 years enrollment plus 10 years follow-up): Post-operative follow-up visits at: 1, 3, 5, 7 and 10 years
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who gave verbal consent to take part in the study at study commencement and written consent retrospectively at 10 years follow-up by signing the informed consent form according to the General data protection Regulation (GDPR) Patient Consent Form"
* Age: =\> 18 years
* Male and Female
* Non- inflammatory degenerative joint disease including osteoarthritis, avascular necrosis \& post traumatic arthritis
* Rheumatoid arthritis,
* Correction of functional deformity
* Revision of failed joint reconstruction or treatment
* Treatment of femoral neck and trochanteric fractures of the proximal femur with femoral head involvement and which are unmanageable using other techniques
Exclusion Criteria
* Patients who are unwilling or unable to give consent, or to comply with the follow-up program
* The patient is known to be pregnant or breastfeeding
* Any vulnerable subjects (= individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate)
* Uncooperative patient or patient with neurologic disorders who are incapable of fol-lowing instruction
* Osteoporosis
* Metabolic disorder which may impair bone formation
* Osteomalacia
* Local and distant foci of infection
* Rapid joint destruction, marked bone loss or bone resorption apparent on roent-genogram
* Vascular insufficiency, muscular atrophy, or neuromuscular disease
* Skeletal immaturity
* Morbid obesity
* Foreign body sensitivity. Where suspected, material sensitivity tests are to be made prior to implantation
* Any condition that may interfere with the survival of the implant such as Paget's disease, Charcot's disease, sickle cell anaemia or traits, lower extremity muscular atrophy or neuromuscular disease'
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zimmer Biomet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMETEU.CR.EU37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.